Yi Xun Tang

Manulife TEDA Fund Management Co. Ltd. (Manulife TEDA FM) is the fund management joint venture between Northern International Trust & Investment Co. Ltd. and Manulife Asset Management (Hong Kong) Ltd. Formerly known as ABN AMRO TEDA Fund Management Co. Ltd., the firm was established in 2002 as Tianjin TEDA Investment Holding Co., Ltd. Manulife TEDA FM is located in Beijing and manages a range of open-end funds, including equity, hybrid, bond and currency funds, for individual and institutional customers.

Penghua Fund Management Co., Ltd. (Penghua) is an independent Chinese investment management firm which was founded in 1998 to manage third party asset, principally through equities and fixed-income. In 2007 they set up a joint venture with Eurizon Financial Group (Intesa Sanpaolo), selling half of their capital to the Italian firm and Guosen Securities Co. Ltd. Headquartered Shenzhen, Penghua manages a range of mutual funds, including open- and closed-end funds, for institutional and retail investors.

ENSEM Therapeutics, Inc. is a drug discovery and development company that specializes in developing small molecule precision medicines for oncology. The company is based in Waltham, MA. The company leverages its unique Kinetic Ensemble® platform to develop innovative drugs. The company has a potential oral CDK2 inhibitor, PI3K?, and a number of early-stage discovery programs at various stages of maturity launched with their Kinetic Ensemble® platform. ENSEM Therapeutics was founded by Shenfang Jin, Qi Zhang, Cheng Luo, and Shenfang Jin has been the CEO since incorporation.